ÂÜÀòÂÒÂ×

Alan Parker has a diverse work experience in the field of translational virotherapies and gene therapy. Alan is currently working as the Head of Solid Cancers at Cardiff University, where they lead a group of researchers focused on developing novel virotherapies for cancer treatment. Previously, they held positions as a Professor, Reader, and Senior Lecturer at the university, where they conducted research on oncolytic adenoviral vectors and advanced cancers. In addition to their academic roles, Alan Parker is the Founder and Chief Scientific Officer of Trocept Therapeutics at Accession Therapeutics Limited. Alan is also actively involved in the field as a Board Member and Treasurer of the British Society for Gene and Cell Therapy and as the co-lead for the immuno-oncology theme of the Cancer Research Strategy for Wales. Alan Parker has also contributed to STEM education as a STEM Ambassador, promoting science and technology careers to children and the general public. Alan'searlier experience includes positions at the University of Glasgow, where they developed adenoviral vectors for gene therapy, and King's College London and the University of Birmingham, where they conducted postdoctoral and doctoral research, respectively.

Alan Parker attended Birkenhead School from 1988 to 1995. Alan then pursued a degree in Genetics at The University of Sheffield from 1995 to 1998.